Despite the recent volatility in the company's stock, TG Therapeutics cancer drugs are on track for approval and will ultimately fill a niche where old generic chemotherapies have failed, says the company's CEO Michael Weiss. Weiss believes that this specific market will triple over the next 10 to 15 years with the introduction of newer, more effective drugs like the ones being developed by TG. And while there are doubters in the stock, Weiss believes he can repeat the success he enjoyed previously at Keryx, which he grew to a $1 billion company at its peak.

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.

More from Video

Jim Cramer's Investing Rule #2: It's OK to Pay Taxes

Jim Cramer's Investing Rule #2: It's OK to Pay Taxes

Video: Here Is Why Carvana Isn't Worried About Amazon

Video: Here Is Why Carvana Isn't Worried About Amazon

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers